Wednesday, March 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Organic Vaccines Partner with NIH for MERS-CoV Countermeasures

by Global Biodefense Staff
November 19, 2014
Middle East Respiratory Syndrome Coronavirus

MERS coronavirus particles (green) on camel epithelial cells. Credit: NIAID, CSU

Organic Vaccines LLC this week announced it has entered into a commercial evaluation license agreement with the National Institutes of Health (NIH) and a three-year collaborative agreement with the US National Cancer Institute (NCI), with a principal goal of developing human monoclonal antibody-based techniques targeting the Middle East Respiratory Syndrome Coronovirus (MERS-CoV).

The agreements were locked in July and September 2014, respectively.

“These agreements shall enable Organic Vaccines to complement its strategy against MERS CoV. During our meeting of September 18th at the control and command center of the Ministry of Health in Jeddah (Saudi Arabia), we have explained the science and exposed our strategy,” said Patrick Rambaud, President and CEO of Organic Vaccines Plc. Our objective is to be at the earliest in a position to offer a stopgap treatment on a compassionate basis. We have already started complementary studies to meet WHO requirements and submit our dossier.”

Organic Vaccines focuses on the development of preventive and therapeutic vaccines produced using the patient’s own white blood cells. Areas of vaccine development cover children vaccines, flu vaccines and HPV adult vaccines (preventive and therapeutic) as well as the implementation of white blood cell banks.

Source: Organic Vaccines press release, adapted.

Tags: CoronavirusMERS-CoVNIH

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC